Safety and Efficacy of ULSC on Disease Severity and Steroid Tapering in Participants With Dermatomyositis/ Polymyositis (DM/PM), Also Known as Idiopathic Inflammatory Myopathy (IIM)

NCT07160205 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

RECRUITING

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Idiopathic Inflammatory Myositis (IIM)
DERMATOMYOSITIS OR POLYMYOSITIS

Interventions

BIOLOGICAL: ULSC (1.5 x 10^8 cells/dose)
BIOLOGICAL: Placebo (no cells)

Sponsor

Restem, LLC.